Metropolis Healthcare542650Quarterly results
Board approves results for quarter and half year ended September 30, 2026; declares interim dividend of INR 1 per share
Board approved the Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
By ScoutQuest · · 3 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4,968.21 | 4,291.91 | +15.8% | 4,502.15 | +10.4% |
| Total income | 5,053.13 | 4,300.82 | +17.5% | 4,553.17 | +11% |
| Profit before tax | 1,024.81 | 710.26 | +44.3% | 777.12 | +31.9% |
| Profit after tax | 754.83 | 528.90 | +42.7% | 568.83 | +32.7% |
| Total comprehensive income | 762.94 | 548.86 | +39% | 597.07 | +27.8% |
| Basic EPS | 3.64 | 2.54 | +43.3% | 2.73 | +33.3% |
- Total income - YoY growth
- +17.5% (year ago 4,300.82)
- Profit after tax - YoY growth
- +42.7% (latest 754.83, year ago 528.90)
- Period
- Quarter ended September 30, 2026 (Unaudited)
Also decided at the meeting
- Declared interim dividend of INR 1/- per equity share of face value INR 2/- each for FY 2026-27; record date Monday, November 09, 2026; payable within 30 days of declaration.
Auditor's review
Conclusion: Unmodified
Notes to the results
- Exceptional item: estimated liability towards gratuity and leave encashment for past service cost under the Labour Codes of Rs. 89.90 million recognised for the year ended March 31, 2026.
- Presentation changed from Rs. in Lakhs to Rs. in Million with effect from the quarter ended June 30, 2026; comparatives restated.
- Company issued and allotted 15,54,95,826 bonus equity shares in the ratio 3:1, approved by shareholders on March 08, 2026.
Dividend declared
- The board declared an Interim Dividend of INR 1/- per equity share of face value INR 2/- for the financial year 2026-27.
- The record date for payment is Monday, November 09, 2026.
- The dividend is to be paid within 30 days of its declaration. Shareholders holding shares on the record date are the ones entitled to receive it.
What the board approved
- The Unaudited Standalone and Consolidated Financial Results of the company for the quarter and half year ended September 30, 2026.
- The limited review report issued by the Statutory Auditors on those results was noted, and the results are being made available on the company's website.
Auditor's conclusion
- Deloitte Haskins & Sells Chartered Accountants LLP reviewed both the standalone statement and the consolidated statement (parent plus subsidiaries).
- In both reports the conclusion is unmodified: nothing came to the auditors' attention that causes them to believe the statements have not disclosed the information required or that they contain any material misstatement.
- The reports state these are reviews, not audits, and that a review is substantially less in scope than an audit. The figures are therefore unaudited interim numbers that have been reviewed.
How the consolidated numbers were put together
- The consolidated statement covers the parent and a long list of subsidiaries, including Ekopath Metropolis Lab Services Private Limited, Amin's Pathology Laboratory Private Limited, DAPIC Metropolis Healthcare Private Limited, Centralab Healthcare Services Private Limited, Metropolis Healthcare (Mauritius) Limited, Metropolis Healthcare Lanka (Pvt) Limited, Core Diagnostics Private Limited, Metropolis Foundation, Scientific Metropolis Pathology Private Limited and Metropolis Quality Solution Private Limited, plus step-down subsidiaries in Mauritius, Ghana, Kenya, Tanzania and Uganda.
- For parts of this group the auditors relied on the reports of other auditors or on information certified by the parent's management, and the conclusion is not modified for that reliance.
Two subsidiaries reviewed by other auditors
- Their interim financial information reflects total assets of Rs. 1,120.39 million as at September 30, 2026.
- Total revenues of Rs. 351.72 million for the quarter and Rs. 667.94 million for the six months ended September 30, 2026.
- Total net profit after tax of Rs. 74.95 million for the quarter and Rs. 112.17 million for the six months.
- Total comprehensive income of Rs. 81.07 million for the quarter and Rs. 143.15 million for the six months, and net cash inflows of Rs. 35.69 million for the six months.
Seven subsidiaries whose interim information was not reviewed by their auditors
- Total assets of Rs. 539.03 million as at September 30, 2026.
- Total revenue of Rs. 143.77 million for the quarter and Rs. 282.48 million for the six months ended September 30, 2026.
- Total profit/(loss) after tax of Rs. (2.14) million for the quarter and Rs. 8.21 million for the six months; total comprehensive income of Rs. 2.27 million and Rs. 14.17 million respectively, and net cash inflows of Rs. 32.03 million for the six months.
- Management's explanation, as recorded in the review report, is that this information is not material to the Group.
What a retail shareholder can take away
- Two decisions came out of the meeting: the interim dividend with a November 09, 2026 record date, and approval of the September-quarter results.
- The auditors' review conclusion on both the standalone and consolidated statements is clean, meaning they did not flag anything in the disclosure or the numbers reviewed.
- The consolidated picture includes several overseas and smaller subsidiaries where other auditors or management-certified numbers were used, so the group figures rest partly on that work.
5,053.13 (Rs. in million)Total income, latest quarter
Total income, year-ago quarter4,300.82 (Rs. in million)
Profit after tax, latest quarter754.83 (Rs. in million)
Also from Metropolis Healthcare
Metropolis Healthcare Ltd press release, Q2 FY27
3 Nov 2026
Metropolis Healthcare Q2 FY27: revenue up 15.8%, profit after tax up 42.7%
3 Nov 2026
Interim dividend of Rs. 1 per share declared; September quarter results approved
3 Nov 2026
More numbers
- Interim dividend per equity shareINR 1/-
- Face value per equity shareINR 2/-
- Dividend payment timeline from declaration30 days
- Two subsidiaries not reviewed by Deloitte: total assetsRs. 1,120.39 million
- Two subsidiaries: total revenues for six monthsRs. 667.94 million
- Two subsidiaries: net profit after tax for six monthsRs. 112.17 million
- Seven subsidiaries not reviewed by their auditors: total assetsRs. 539.03 million
- Seven subsidiaries: total profit/(loss) after tax for the quarterRs. (2.14) million
- Total income, latest quarter5,053.13 (Rs. in million)
- Total income, year-ago quarter4,300.82 (Rs. in million)
- Total income, previous quarter4,553.17 (Rs. in million)
- Total comprehensive income, latest quarter762.94 (Rs. in million)
- Total comprehensive income, year-ago quarter548.86 (Rs. in million)
- Total comprehensive income, previous quarter597.07 (Rs. in million)
- Profit after tax, latest quarter754.83 (Rs. in million)
- Profit after tax, year-ago quarter528.90 (Rs. in million)
- Profit after tax, previous quarter568.83 (Rs. in million)
- Revenue from operations, latest quarter4,968.21 (Rs. in million)
- Revenue from operations, year-ago quarter4,291.91 (Rs. in million)
- Revenue from operations, previous quarter4,502.15 (Rs. in million)
- Profit before tax, latest quarter1,024.81 (Rs. in million)
- Profit before tax, year-ago quarter710.26 (Rs. in million)
- Profit before tax, previous quarter777.12 (Rs. in million)
Source: BSE · 3 Nov 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.